Latest News for: q32

Edit

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in ...

The Paris News 30 Sep 2026
-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- ....
Edit

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 (Form 8-K) (Q32 Bio Inc)

Public Technologies 30 Sep 2026
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 ... WALTHAM, Mass., September 30, 2026 - Q32 Bio Inc.
Edit

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

PR Newswire 30 Sep 2026
-- Data supports further development of bempikibart as a chronic treatment in alopecia areata; Q32 Bio intends to advance a registration-directed program in the first half of 2027 -- ... 30, 2026 /PRNewswire/ -- Q32 Bio Inc ... About Q32 Bio ... SOURCE Q32 Bio.
Edit

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer (Form 8-K) (Q32 Bio Inc)

Public Technologies 14 Sep 2026
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer ... WALTHAM, Mass., September 14, 2026 - Q32 Bio Inc ... We are thrilled to welcome José and Ellie to the Q32 Bio team.".
Edit

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Morgan Citizen 15 Jul 2026
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio ...
Edit

Notice of Effectiveness (Form EFFECT) (Q32 Bio Inc)

Public Technologies 14 Jul 2026
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 ... Q32 Bio Inc ... Q32 Bio Inc.
Edit

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial ...

Corsicana Daily Sun 13 Jul 2026
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis -- ....
Edit

Material Event (Form 8-K) (Q32 Bio Inc)

Public Technologies 13 Jul 2026
). The text version of this document is not available ... Q32 Bio Inc.
Edit

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata (Form 8-K) (Q32 Bio Inc)

Public Technologies 13 Jul 2026
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata ... - Q32 Bio to host conference call and webcast today, July 13, 2026, at 8.00 a.m ... About Q32 Bio ... Q32 Bio Inc.
Edit

Why Q32 Bio investors should take profits in the stock after 81% rally

Invezz 13 Jul 2026
Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial ... Including today’s rally, Q32 Bio stock is ...
Edit

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire 13 Jul 2026
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc ... All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Q32 Bio ... About Q32 Bio ... SOURCE Q32 Bio.
Edit

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

PR Newswire 13 Jul 2026
-- Q32 Bio to host conference call and webcast today, July 13, 2026, at 8.00 a.m ... WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc ... About Q32 Bio ... Availability of Other Information About Q32 Bio ... SOURCE Q32 Bio.
Edit

Supplemental Prospectus (Form 424B5) (Q32 Bio Inc)

Public Technologies 13 Jul 2026
and referred to herein as Legacy Q32), with Legacy Q32 continuing as the surviving entity as a wholly-owned subsidiary of Homology (the "Merger") ... and referred to herein as Legacy Q32), with ...
Edit

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of ...

Morgan Citizen 11 Jul 2026
-- Conference call to be held Monday, July 13th at 8.00 a.m. E.T. -- ... .
Edit

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

PR Newswire 10 Jul 2026
WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc ... Following the announcement, Q32 Bio will host a conference call and webcast at 8.00 a.m ... About Q32 Bio ... Availability of Other Information About Q32 Bio ... SOURCE Q32 Bio.

Article Search

tools
×
×
×
×